neuromuscular disease: Any disease that impairs the functioning of the muscles, either directly, being pathologies of the voluntary muscle, or indirectly, being pathologies of nerves or neuromuscular junctions
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
154 |
4. Check minimum number of eventsNone |
154 |
5. Include endpointsNone |
154 |
6. Filter based on genotype QC (FinnGen only) |
132 |
Control definitions (FinnGen only)
- Control exclude
- G6_MYONEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other and unspecified myoneural disorders
based on the number of shared cases.
Similar with more cases:
- Diseases of the myoneural junction and muscle
- Neurological diseases
- Neurological diseases, wide definition
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1011 | 506 | 489 |
| Only index persons | 841 | 448 | 393 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 61.18 | 58.65 | 63.71 |
| Only index persons | 59.26 | 56.81 | 62.04 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 132 | 79 | 53 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | 54.31 | 48.94 | 62.33 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 142
- Matched controls
- 1420
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G70.9
ICD-10 Finland
Myoneural disorder, unspecified
+∞
139.6
110
*
N07AA02
ATC
pyridostigmine; systemic
986.0
113.9
97
*
G70.0
ICD-10 Finland
Myasthenia gravis
+∞
103.0
86
*
108
Kela drug reimbursment
Myasthenia gravis
+∞
98.8
83
*
L04AX01
ATC
azathioprine; systemic
45.0
81.4
52
18
G70.8
ICD-10 Finland
Other specified myoneural disorders
+∞
38.3
35
*
A12BA01
ATC
potassium chloride; oral
17.7
36.0
32
23
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
8.6
26.8
41
64
N07AA03
ATC
distigmine; systemic
100.4
23.5
25
*
G70
ICD-10 Finland
Myasthenia gravis and other myoneural disorders
+∞
21.4
20
*
R03CA02
ATC
ephedrine; oral
85.9
20.3
22
*
H02.4
ICD-10 Finland
Ptosis of eyelid
16.9
18.8
30
22
N99
ICPC
Neurological disease other
191.6
16.9
17
*
3580A
ICD-9 Finland
Myoneural disorders, Myasthenia gravis
+∞
15.9
15
*
G72.9
ICD-10 Finland
Myopathy, unspecified
178.9
15.8
16
*
H02AB07
ATC
prednisone; oral
4.7
13.0
36
96
GEC24
NOMESCO Finland
Thoracoscopic thymectomy
+∞
12.7
12
*
R13
ICD-10 Finland
Dysphagia
5.5
11.7
25
53
5872
FHL
Thymic exploration or thymectomy
+∞
11.6
11
*
H53.2
ICD-10 Finland
Diplopia
11.5
11.5
21
21
G70.28
ICD-10 Finland
Other congenital and developmental myasthenia
+∞
10.5
10
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.1
9.9
90
505
R4130
NOMESCO Finland
Speech therapy
10.7
9.6
18
19
G70.20
ICD-10 Finland
Congenital and developmental myasthenia
+∞
9.5
9
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.0
9.2
70
351
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.5
9.2
39
139
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
5.5
9.1
19
39
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.0
8.7
20
45
73300
ICD-8 Finland
Other diseases of muscle, tendon and fascia, Myasthenia gravis
+∞
8.4
8
*
ZX120
NOMESCO Finland
Intravenous
3.8
8.0
28
87
L28
ICPC
Limited function/disability (L)
3.1
8.0
42
170
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.7
7.6
27
85
G73.1*C80.99
ICD-10 Finland
Eaton-Lambert syndrome
+∞
7.3
7
*
3589X
ICD-9 Finland
Myoneural disorders, unspecified
+∞
7.3
7
*
GEC26
NOMESCO Finland
Mediastinoscopic thymectomy
+∞
7.3
7
*
R03DA04
ATC
theophylline; systemic, rectal
7.7
7.2
16
23
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
4.4
6.9
18
45
N29
ICPC
Neurological sympt/complt other
17.8
6.8
10
6
H02AB06
ATC
prednisolone; systemic
2.5
6.8
85
525
GEC23
NOMESCO Finland
Transsternal thymectomy
+∞
6.3
6
*
2AB04, ,
NOMESCO Finland
+∞
6.3
6
*
G70.1
ICD-10 Finland
Toxic myoneural disorders
+∞
6.3
6
*
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
+∞
6.3
6
*
G72.8
ICD-10 Finland
Other specified myopathies
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
35
10
45.81
29.07
1.3
1.2
35.05
—
nmol/l
—
16
0
104
628
3.45
10.15
7.9
7.7
1.21
1.21
mmol/l
0.07
93
544
92
567
2.77
7.74
8.4
6.5
1.21
1.21
mmol/l
0.33
87
530
11
8
14.76
7.01
1.4
1.4
—
—
—
0
0
104
733
2.57
5.88
18.7
10.7
4.00
3.93
e9/l
0.15
96
639
24
84
3.23
5.68
1.9
1.5
—
—
—
0
0
5
0
+∞
5.24
1.0
0.0
—
—
—
0
0
82
539
2.23
5.18
2.7
2.1
92.39
96.58
pmol/l
0.25
41
276
20
67
3.31
5.06
2.4
1.6
—
—
—
0
0
8
8
10.50
4.58
3.0
2.9
—
—
—
0
0
15
37
4.41
4.57
1.3
1.0
—
—
—
0
0
30
134
2.57
4.55
2.4
2.1
330.93
371.05
nmol/l
0.68
30
126
38
192
2.34
4.42
2.8
1.9
29.29
28.71
s
0.25
38
187
83
571
2.09
4.41
2.8
2.7
74.71
78.09
nmol/l
0.47
78
513
34
166
2.38
4.26
2.6
1.7
—
—
—
0
0
22
89
2.74
4.03
9.5
7.1
23.99
25.15
mmol/l
1.00
22
89
40
216
2.19
3.94
2.5
1.8
—
—
—
0
0
95
708
2.03
3.82
6.1
3.7
0.00
0.00
estimate
-0.00
21
161
6
5
12.44
3.79
1.5
1.0
1158.50
1989.20
miu/ml
—
6
5
53
325
2.01
3.71
3.1
2.2
2.70
2.93
mg/l
0.28
45
278
9
17
5.57
3.57
1.1
1.1
—
—
—
0
0
31
159
2.21
3.43
2.7
6.9
1.04
1.03
mmol/l
0.05
31
144
93
703
1.94
3.41
6.3
3.7
0.00
0.00
estimate
-0.00
21
158
8
14
5.98
3.39
1.1
1.0
—
—
—
0
0
94
716
1.93
3.33
6.3
3.7
0.00
0.00
estimate
-0.00
18
146
13
39
3.56
3.33
1.2
1.4
—
—
—
0
0
19
79
2.62
3.30
11.7
10.2
94.68
94.29
%
0.18
19
79
6
7
8.88
3.29
2.0
3.0
—
—
—
0
0
59
392
1.86
3.17
3.6
3.0
1107.89
981.97
ng/l
0.15
47
322
47
291
1.92
3.13
2.0
1.7
1.36
1.62
mg/l
0.23
37
231
8
16
5.23
3.10
1.0
1.1
—
—
—
0
0
5
5
10.30
3.00
1.0
1.4
—
—
—
0
0
55
365
1.83
2.92
5.4
3.1
0.33
0.46
e6/l
0.25
47
273
116
971
2.06
2.85
5.1
4.5
15.46
14.78
pmol/l
1.41
110
889
29
161
2.01
2.60
2.7
1.7
—
—
—
0
0
21
103
2.22
2.57
2.8
2.1
4.30
4.59
ug/l
0.09
15
93
14
57
2.62
2.54
1.5
1.4
—
—
—
0
0
55
379
1.74
2.51
1.9
1.8
17.66
21.23
nmol/l
1.23
42
319
39
244
1.82
2.45
7.5
3.2
38.72
276.01
ng/l
1.13
33
178
6
13
4.77
2.29
3.0
1.5
2.57
0.36
mmol/l
—
6
13
55
388
1.68
2.26
6.6
3.6
0.00
0.00
estimate
-0.00
18
142
10
35
2.99
2.26
6.0
3.3
4.40
2.58
index
—
5
24
5
9
5.71
2.23
1.8
1.2
14.20
12.56
u/l
—
5
9
30
181
1.83
2.10
9.5
7.0
104.73
104.38
mmol/l
0.12
30
181
5
10
5.14
2.09
1.2
1.0
—
—
—
0
0
20
107
2.01
1.98
1.6
2.8
64.57
67.65
g/l
1.04
20
102
6
16
3.87
1.95
3.2
1.8
14.62
16.30
ug/l
—
6
16
9
34
2.76
1.90
1.1
1.1
—
—
—
0
0
9
34
2.76
1.90
1.1
1.1
—
—
—
0
0
8
29
2.86
1.82
1.4
1.4
—
—
—
0
0
8
29
2.86
1.82
1.4
1.4
—
—
—
0
0
66
510
1.55
1.78
4.4
3.9
28.92
38.59
ng/l
0.59
51
356
10
40
2.61
1.70
10.0
1.9
27.01
25.09
mmol/l
—
10
40
43
309
1.56
1.57
3.0
2.4
—
—
—
0
0
11
51
2.25
1.55
3.2
1.5
0.22
0.24
g/l
0.27
11
51
6
21
2.94
1.52
1.5
1.2
—
—
nmol/l
—
0
0
18
103
1.86
1.49
4.0
8.0
7.24
8.92
mmol/l
0.71
18
96
30
200
1.63
1.48
5.7
3.1
2.72
3.03
e6/l
0.09
18
92
9
39
2.39
1.46
1.3
1.7
—
—
—
0
0
10
46
2.26
1.43
1.4
1.3
—
—
—
0
0
37
262
1.56
1.43
1.3
1.3
10.80
26.11
iu/ml
—
5
82
14
75
1.96
1.40
3.8
3.0
76.50
104.03
ng/l
0.50
14
66
67
541
1.45
1.37
6.5
3.6
0.00
0.00
estimate
-0.00
19
134
128
1183
1.83
1.34
27.3
15.4
86.17
81.88
ml/min/173m2
1.63
119
1102
9
43
2.17
1.33
1.3
1.1
—
5.16
—
0
7
58
458
1.45
1.32
3.1
3.4
2.34
2.36
mmol/l
0.25
53
422
29
198
1.58
1.30
2.0
1.7
1199.95
1222.76
nmol/l
0.06
22
150
99
866
1.47
1.29
3.9
3.3
48.31
47.68
u/l
0.02
94
818
131
1225
1.90
1.22
31.2
15.5
18.53
22.65
mg/l
1.26
119
1002
8
40
2.06
1.14
1.9
1.5
0.00
0.00
g/l
—
8
40
8
41
2.01
1.10
1.1
1.2
—
—
—
0
0
5
21
2.43
1.10
4.8
3.3
2.06
3.48
nmol/l
—
5
21
7
33
2.18
1.07
1.7
1.4
—
—
—
0
0
7
35
2.05
1.01
1.3
1.4
—
—
—
0
0
10
54
1.92
0.99
1.1
1.3
—
—
—
0
0
50
402
1.38
0.99
5.2
3.2
0.00
0.01
estimate
0.50
15
130
15
93
1.69
0.98
1.4
1.2
55.57
359.81
u/ml
0.97
15
86
6
27
2.27
0.94
1.3
1.2
—
—
—
0
0
30
222
1.45
0.94
5.2
2.9
1.52
1.09
e6/l
0.30
19
113
22
153
1.52
0.93
4.8
5.2
29.94
32.58
%
0.76
16
98
6
28
2.19
0.92
1.8
1.1
—
—
—
0
0
8
42
1.96
0.90
1.4
1.9
—
—
—
0
0
38
297
1.38
0.88
7.7
3.6
1.02
1.02
kg/l
0.09
32
191
8
45
1.82
0.86
1.9
1.5
0.00
0.00
g/l
—
8
40
11
65
1.75
0.85
1.2
2.6
32.82
40.43
u/l
0.71
11
57
5
23
2.22
0.77
1.2
1.9
10.20
10.43
mmol/l
—
5
23
5
24
2.12
0.75
1.2
1.0
—
—
—
0
0
20
146
1.43
0.68
16.0
7.2
—
—
—
0
0
31
245
1.34
0.67
1.3
1.3
1.44
5.98
u/ml
—
8
98
5
29
1.75
0.64
1.8
3.4
6.30
10.41
pmol/l
—
5
29
0
20
0.00
0.61
0.0
1.0
—
—
—
0
0
0
20
0.00
0.61
0.0
1.2
—
1.94
—
0
10
68
604
1.24
0.59
5.1
2.8
—
—
estimate
—
0
0
17
124
1.42
0.59
3.3
3.5
—
—
—
0
0
6
35
1.75
0.58
1.3
2.0
—
—
—
0
0
11
75
1.51
0.52
4.7
2.7
0.70
0.62
%
0.24
11
75
83
762
1.21
0.50
3.7
3.2
—
—
—
0
0
5
31
1.63
0.43
1.6
1.5
—
—
—
0
0
61
550
1.19
0.43
1.8
1.9
1.55
1.34
mmol/l
0.92
52
459
0
17
0.00
0.41
0.0
1.2
—
4.69
—
0
7
10
71
1.44
0.40
1.4
1.8
—
—
—
0
0
5
35
1.44
0.39
2.0
1.5
—
—
—
0
0
18
220
0.79
0.35
1.7
1.4
—
—
—
0
0
6
43
1.41
0.35
1.8
1.6
—
—
—
0
0
6
44
1.38
0.35
1.5
1.5
2112.20
934.45
mu/l
—
6
38
10
76
1.34
0.29
5.1
2.7
0.83
1.27
%
—
10
76
36
322
1.16
0.27
1.4
1.3
0.62
1.15
u/ml
—
9
92
119
1220
0.85
0.24
5.2
5.4
4.62
4.63
mmol/l
0.04
114
1141
5
38
1.33
0.23
2.0
1.5
—
—
—
0
0
5
40
1.26
0.22
2.0
1.6
—
—
—
0
0
5
42
1.20
0.21
2.0
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
5.4
—
389.10
—
0
10
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
6
49
1.23
0.20
3.3
2.2
—
—
—
0
0
16
137
1.19
0.20
1.5
1.8
—
—
—
0
0
119
1215
0.87
0.18
5.2
5.3
1.45
1.49
mmol/l
0.34
112
1127
5
66
0.75
0.17
1.0
1.1
—
—
—
0
0
121
1190
1.11
0.12
5.4
5.3
6.04
5.94
mmol/l
0.41
115
1097
10
86
1.18
0.11
1.5
1.8
—
—
—
0
0
105
1030
1.07
0.10
38.8
20.0
13.79
13.65
%
0.59
105
1021
114
1156
0.93
0.08
4.3
4.6
1.38
1.28
mmol/l
0.68
106
1068
25
235
1.08
0.08
2.0
1.5
—
—
—
0
0
122
1233
0.93
0.07
6.0
6.1
2.72
2.70
mmol/l
0.11
116
1148
30
287
1.06
0.05
3.6
4.9
23.47
22.86
%
0.08
15
152
45
436
1.05
0.05
4.1
4.0
6.90
8.78
mg/mmol
0.22
30
267
12
110
1.10
0.05
2.0
1.3
—
—
—
0
0
118
1170
1.05
0.03
7.1
6.5
40.45
39.40
mmol/mol
0.55
113
1100
23
223
1.04
0.01
2.7
3.2
0.69
0.85
ug/l
0.60
15
142
15
148
1.02
0.00
1.7
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.2
—
13.63
—
0
9
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
22.60
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
96.00
—
0
5
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
68.40
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint G6_MYONEUOTHUNS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MYONEUOTHUNS | 2.125 [1.59, 2.84] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.074 |
During the follow-up period (1.1.1998 — 31.12.2019), 123 out of 407 females with G6_MYONEUOTHUNS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MYONEUOTHUNS | 2.046 [1.58, 2.65] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 166 out of 388 males with G6_MYONEUOTHUNS died.
Mortality risk
Mortality risk for people of age
years, who have G6_MYONEUOTHUNS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.187% | 0.44% |
| 5 | 1.036% | 2.468% |
| 10 | 2.73% | 5.883% |
| 15 | 5.304% | 10.882% |
| 20 | 9.42% | 18.602% |
Relationships between endpoints
↥Index endpoint: G6_MYONEUOTHUNS – Other and unspecified myoneural disorders
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data